Advances in the biology of malignant pleural mesothelioma

Cancer Treatment Reviews

Volumn 37, Issue 7, 2011, Pages 543-558

  Zucali, P A ^a   Ceresoli, G L ^b   De Vincenzo, F ^a   Simonelli, M ^a   Lorenzi, E ^a   Gianoncelli, L ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

Author keywords

Malignant mesothelioma; Molecular pathways; Targeted therapy

Indexed keywords

BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; BUTYRIC ACID; CARBOPLATIN; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; I KAPPA B; IMATINIB; LEXATUMUMAB; MAPATUMUMAB; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; RANPIRNASE; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB; VORINOSTAT;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; AUTOCRINE EFFECT; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CONCENTRATION RESPONSE; DNA METHYLATION; DRUG ANTAGONISM; DRUG POTENTIATION; EARLY DIAGNOSIS; EPIGENETICS; GENE CONTROL; GENE MUTATION; HODGKIN DISEASE; HUMAN; LUNG CANCER; LYMPHOMA; MACROPHAGE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PLEURA MESOTHELIOMA; PREDICTION; PROGNOSIS; REVIEW; SIMIAN VIRUS 40; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MESOTHELIOMA; NEOPLASM PROTEINS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80052356301     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.01.001     Document Type: Review

References (218)

1. Robinson B.W.S., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
2. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29:2-17.
3. Zucali P.A., De Vincenzo F., Simonelli M., Santoro A. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther 2009, 9:453-467.
4. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998, 16:145-152.
5. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
6. Zucali P.A., Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006, 42:2706-2714.
7. Fennell D.A., Gaudino G., O'Byrne K.J., Mutti L., van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008, 5:136-147.
8. Belli C., Fennell D., Giovannini M., Gaudino G., Mutti L. Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 2009, 14:423-437.
9. Pasello G., Favaretto A. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets 2009, 10:1235-1244.
10. Ismail-Khan R., Robinson L.A., Williams C.C., et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Contr 2006, 13:255-263.
11. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29:2-17.
12. Bocchetta M., Di Resta I., Powers A., et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000, 97:10214-10219.
13. Yang H., Bocchetta M., Kroczynska B., et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB dependent pathway, a possibile mechanism for asbestos induced oncogenesis. Proc Natl Acad Sci USA 2006, 103:10397-10402.
14. Xu A., Zhou H., Yu D.Z., et al. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect 2002, 110:1003-1008.
15. Shukla A., Gulumian M., Hei T.K., et al. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 2003, 34:1117-1129.
16. Yang H., Rivera Z., Jube S., et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 2010, 107:12611-12616.
17. Xu A., Wu L.J., Santella R.M., et al. Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells. Cancer Res 1999, 59:5922-5926.
18. Galffy G., Mohammed K.A., Dowling P.A., et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999, 59:367-371.
19. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
20. Cacciotti P., Libener R., Betta P., et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001, 98:12032-12037.
21. Liu Z., Klominek J. Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors. Anticancer Res 2004, 24:1625-1630.
22. Ramos-Nino M.E., Timblin C.R., Mossman B.T. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002, 62:6065-6069.
23. Carbone M., Pass H.I., Miele L., et al. New developments about the association of SV40 with human mesothelioma. Oncogene 2003, 22:5173-5180.
24. Pass H.I., Bocchetta M., Carbone M. Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin 2004, 14:489-495.
25. Cutrone R., Lednicky J., Dunn G., et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res 2005, 6:10273-10279.
26. Wong M., Pagano J.S., Schiller J.T., et al. New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst 2002, 94:1832-1836.
27. Bocchetta M., Eliasz S., De Marco M.A., et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008, 68:1022-1029.
28. Foddis R., De Rienzo A., Broccoli D., et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002, 21:1434-1442.
29. Bocchetta M., Miele L., Pass H.I., Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003, 22:81-89.
30. Kroczynska B., Cutrone R., Bocchetta M., et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006, 103:14128-14133.
31. Cavazza A., Travis L.B., Travis W.D., et al. Post-irradiation malignant mesothelioma. Cancer 1996, 77:1379-1385.
32. Teta M.J., Lau E., Sceurman B.K., et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007, 109:1432-1438.
33. Saffiotti U. Mesothelioma carcinogenesis: in vivo models. Malignant mesothelioma 2005, Springer, New York. H.I. Pass, N.J. Vogelzang, M. Carbone (Eds.).
34. Carbone M., Emri S., Dogan A.U., et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007, 7:147-154.
35. Narasimhan S.R., Yang L., Gerwin B.I., Broaddus V.C. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of bcl-2 and bax. Am J Physiol 1998, 275:L165-L171.
36. Destro A., Ceresoli G.L., Baryshnikoa E., et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2008, 59:369-376.
37. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
38. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116.
39. Suzuki M., Toyooka S., Shivapurkar N., et al. Aberant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 2005, 24:1302-1308.
40. Murthy S.S., Testa J.R. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999, 180:150-157.
41. Testa J.R., Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol 2001, 11:31-38.
42. Hirao T., Bueno R., Chen C.J., Gordon G.J., Heilig E., Kelsey K.T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002, 23:1127-1130.
43. He B., Lee A.Y., Dadfarmay S., et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells. Cancer Res 2005, 65:743-748.
44. Lee A.Y., He B., You L., et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004, 23:6672-6676.
45. Murty S.S., Shen T., De Rienzo A., et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000, 19:410-416.
46. Ohta Y., Shridhar V., Kalemkerian G.P., Bright R.K., Watanabe Y., Pass H.I. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 1999, 85:2570-2576.
47. Shigematsu H., Suzuki M., Takahashi T., et al. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 2005, 113:600-604.
48. Shivapurkar N., Toyooka S., Toyooka K.O., et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004, 109:786-792.
49. Toyooka S., Pass H.I., Shivapurkar N., et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001, 61:5727-5730.
50. Batra S., Shi Y., Kuchenbecker K.M., et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 2006, 342:1228-1232.
51. Tomii K., Tsukuda K., Toyooka S., et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 2007, 120:566-573.
52. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001, 25:562-568.
53. Symanowski J., Vogelzang N., Zawel L., et al. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009, 4:149-160.
54. Vandermeers F., Hubert P., Delvenne P., et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15:2818-2828.
55. Shao Y.L.J., Cheng C., Cui L., et al. Reversible histone acetylation involved in transcriptional regulation of WT1 gene. Acta Biochim Biophys Sin 2007, 39:931-938.
56. Krug L.M., Curley T., Schwartz L., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7:257-261.
57. Krug LM, Marangolo M, Kindler HL, et al. A phase III, randomized, double-blind, placebo-controlled trial of vorinostat in patients with advanced malignant pleural mesothelioma (MPM) previously treated with systemic chemotherapy. In: Proceedings of the IX International Conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008; abs. 223.
58. Ramalingam S.S., Belani C.P., Ruel C., et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009, 4:97-101.
59. Marchion D., Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007, 7:583.
60. Chen L., Vogelzang N.J., Blumenschein G., et al. Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer. J Clin Oncol 2007, 25:180-188.
61. Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2010. [Epub ahead of print].
62. Papp T., Shipper H., Pemsel H., et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001, 18:425-433.
63. Papp T., Shipper H., Pemsel H., et al. Mutational analysis of the PTEN/MMAC1 tumor suppressor gene in primary human malignant mesotheliomas. Oncol Rep 2001, 8:1375-1379.
64. Cheng J.Q., Lee W.C., Klein M.A., Cheng G.Z., Jhanwar S.C., Testa J.R. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999, 24:238-242.
65. Sekido Y., Pass H.I., Bader S., et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995, 55:1227-1231.
66. Deguen B., Goutebroze L., Giovannini M., et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998, 77:554-560.
67. Poulikakos P.I., Xiao G.H., Gallagher R., et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006, 25:5960-5968.
68. Fleury-Feith J., Lecomte C., Renier A., et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos induced peritoneal tumours. Oncogene 2003, 22:3799-3805.
69. Lecomte C., Andujar P., Renier A., et al. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005, 4:1862-1869.
70. Jongsma J., van Montfort E., Vooijs M., et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008, 13:261-271.
71. Thurneysen C., Opitz I., Kurtz S., et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009, 64:140-147.
72. Lopez-Lago M.A., Okada T., Murillo M.M., et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009, 29:4235-4249.
73. Gordon G.J., Mani M., Mukhopadhyay L., et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007, 211:447-454.
74. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
75. Lenz H.J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003, 29:41-48.
76. Sun X., Gulyas M., Hjerpe A., Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 2006, 232:161-169.
77. Borczuk A.C., Cappellini G.C., Kim H.K., Hesdorffer M., Taub R.N., Powell C.A. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2006, 26:610-617.
78. Gordon G.I., Mani M., Maulik G., et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008, 61:549-558.
79. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410.
80. McManus D.C., Lefebvre C.A., Cherton-Horvat G., et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
81. Wang Y., Rishi A.K., Puliyappadamba V.T., et al. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 2010, 66:455-466.
82. Sartore-Bianchi A., Gasparri F., Galvani A., et al. Bortezomib inhibits nuclear factor-KB - dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13:5942-5951.
83. ; NCT00513877. http://www.clinicaltrials.gov.
84. ; NCT00458913. http://www.clinicaltrials.gov.
85. ; NCT 00996385. http://www.clinicaltrials.gov.
86. Mikulski S.M., Costanzi J.J., Vogelzang N.J., et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002, 20:274-281.
87. Reck M, Krzakowski M, Jassem J, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). J Clin Oncol 2009;27:15s (suppl; abstr 7507).
88. Kratzke R.A., Otterson G.A., Lincoln C.E., et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995, 87:1870-1875.
89. Papp T., Schipper H., Pemsel H., et al. Mutational analysis of Nras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001, 18:425-433.
90. Chiosea S., Krasinskas A., Cagle P.T., Mitchell K.A., Zander D.S., Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008, 21:742-747.
91. Cheng J.Q., Jhanwar S.C., Klein W.M., et al. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547-5551.
92. Wong L., Zhou J., Anderson D., Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136.
93. Frizelle S.P., Rubins J.B., Zhou J.X., Curiel D.T., Kratzke R.A. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000, 7:1421-1425.
94. Frizelle S.P., Grim J., Zhou J., et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998, 16:3087-3095.
95. Yang C.T., You L., Yeh C.C., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000, 92:636-641.
96. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
97. Yaswen P., Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007, 128:233-234.
98. Waldman T., Kinzler K.W., Vogelstein B. P21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
99. Lazzarini R., Moretti S., Orecchia S., et al. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 2008, 14(16):5099-5107.
100. Investigation Brochure for PHA-848125AC, Version 5. Nerviano Medical Sciences; 2008. Document No. CDKO-125a-IB5.
101. Davidson B., Reich R., Lazarovici P., et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004, 44:159-165.
102. Protocol for Study CDKO-125a-005, Version 29 September 2008. Nerviano Medical Sciences, 2008. Document No CDKO-125a-005-P.
103. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288.
104. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
105. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
106. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-885.
107. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005, 23:9394-9407.
108. Kim K.U., Wilson S.M., Abayasiriwardana K.S., et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005, 33:541-548.
109. Rippo M.R., Moretti S., Vescovi S., et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004, 23:7753-7760.
110. Liu W., Bodle E., Chen J.Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001, 25:111-118.
111. Tomasetti M., Rippo M.R., Alleva R., et al. Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer 2004, 90:1644-1653.
112. Belyanskaya L.L., Marti T.M., Hopkins-Donaldson S., et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007, 6:66.
113. Yang E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996, 88:386-401.
114. Krajewski S., Blomqvist C., Franssila K., et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995, 55:4471-4478.
115. Soini Y., Kinnula V., Kaarteenaho-Wiik R., Kurttila E., Linnainmaa K., Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 1999, 5:3508-3515.
116. Hopkins-Donaldson S., Cathomas R., Simoes-Wust A.P., et al. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 2003, 106:160-166.
117. Smythe W.R., Mohuiddin I., Ozveran M., Cao X.X. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002, 123:1191-1198.
118. Pataer A., Smythe W.R., Yu R., et al. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001, 121:61-67.
119. Mohiuddin I., Cao X., Fang B., Nishizaki M., Smythe W.R. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 2001, 8:547-554.
120. Ozvaran M.K., Cao X.X., Miller S.D., et al. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 2004, 3:545-550.
121. Zhu H., Guo W., Zhang L., et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005, 4:451-456.
122. Cao X., Rodarte C., Zhang L., Morgan C.D., Littlejohn J., Smythe W.R. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in Mesothelioma. Cancer Biol Ther 2007, 6:1-7.
123. Singhal S., Wiewrodt R., Malden L.D., et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003, 9:3080-3097.
124. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
125. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
126. Klabatsa A., Sheaff M.T., Steele J.P.C., Evans M.T., Rudd R.M., Fennell D.A. Expression and prognostic significance of hypoxia-inducible factor 1 (HIF-1) in malignant pleural mesothelioma (MPM). Lung Cancer 2006, 51:53-59.
127. Barbone D., Yang T.M., Morgan J.R., Gaudino G., Broaddus V.C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008, 283:13021-13030.
128. ; NCT00770120. http://www.clinicaltrials.gov.
129. ; NCT01024946. http://www.clinicaltrials.gov.
130. Pache J.C., Janssen Y.M., Walsh E.S., et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 1998, 152:333-340.
131. Heintz N.H., Janssen Y.M., Mossman B.T. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA 1993, 3299-3303.
132. Janssen Y.M., Heintz N.H., Mossman B.T. Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-l-cysteine in mesothelial cells. Cancer Res 1995, 55:2085-2089.
133. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990, 61:924-926.
134. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
135. Edwards J.G., Swinson D.E.B., Jones J.L., Waller D.A., O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407.
136. Janne P.A., Taffaro M.L., Salgia R., Johnson B.E. Inhibition of epidermal growth factor signalling in malignant pleural mesothelioma. Cancer Res 2002, 62:5242-5247.
137. Cole G.W., Alleva A.M., Reddy R.M., et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 2005, 129:1010-1017.
138. Govindan R., Kratzke R.A., Hernod J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
139. Lee CW, Anderson H, Martins H, et al. A phase II trial of gefitinib in patients with malignant pleural mesothelioma. Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
140. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406-2413.
141. Cortese J.F., Gowda A.L., Wali A., Eliason J.F., Pass H.I., Everson R.B. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006, 118:521-522.
142. Zucali P.A., Gallegos Ruiz M., Giovannetti E., et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008, 19:1605-1612.
143. Kawaguchi K., Murakami H., Taniguchi T., et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009, 30:1097-1105.
144. Langerak A., van der Linden-van Beurden C.A., Versnel M.A. Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996, 1305:63-70.
145. Porta C., Mutti L., Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59:149-150.
146. Dorai T., Kobayashi H., Holland J.F., Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 1994, 46:437-444.
147. Bertino P., Porta C., Barbone D., et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007, 62:690-695.
148. Bertino P., Piccardi F., Porta C., et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008, 14:541-548.
149. Mathy A., Baas P., Dalesio O., Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50:83-86.
150. Porta C., Mutti L., Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59:149-150.
151. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22:228S (abstr 912).
152. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL. A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). J Clin Oncol, 2004. In: ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No. 14S (July 15 Supplement), 2004:7200.
153. Ali Y., Lin Y., Gharibo M.M., et al. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 2007, 13:5876-5882.
154. ; NCT00551252. http://www.clinicaltrials.gov.
155. ; NCT00402766. http://www.clinicaltrials.gov.
156. Linder C., Linder S., Munck-Wikland E., Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998, 18:2063-2068.
157. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
158. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathos 1999, 189:72-78.
159. Cacciotti P., Strizzi L., Vianale G., et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002, 26:189-193.
160. Demirag F., Unsal E., Yilmaz A., Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005, 128:3382-3387.
161. Edwards J.G., Swinson D.E., Jones J.L., Muller S., Waller D.A., O'Byrne K.J. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003, 124:1916-1923.
162. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in Malignant Mesothelioma: a University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 2001;20 (abstr 1359).
163. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Presented at: 42th ASCO Annual Meeting. Atlanta, GA, USA, 2-6 June 2006.
164. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
165. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant pleural mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:7707.
166. Nowak A, Millward M, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). In: Proceedings of the IX International Conference of the IMIG (International Mesothelioma Interest Group), Amsterdam, The Netherlands; 2008 [abs.116].
167. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
168. Francis R.J., Byrne M.J., Van der Schaaf A.A., et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007, 48:1449-1458.
169. Ceresoli G.L., Chiti A., Zucali P.A., et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18-F fluorodeoxyglucose. J Clin Oncol 2006, 24:4587-4593.
170. Buckstein R., Meyer R.M., Seymour L., et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol 2007, 14:154-161.
171. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients (pts) with malignant mesothelioma. J Clin Oncol 2007;25:391s [suppl; abstr 7526].
172. Ceresoli GL, Zucali PA, De Vincenzo F, et al. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma. Presented at: The 9th International conference of the IMIG. Amsterdam, NL, 25-27 September 2008.
173. ; NCT00295503. http://www.clinicaltrials.gov.
174. NCT00604461. http://www.clinicaltrials.gov.
175. ; NCT00651456. http://www.clinicaltrials.gov.
176. Jackman D.M., Kindler H.L., Yeap B.Y., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113:808-814.
177. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
178. Ogino H., Yano S., Kakiuchi S., et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 2008, 265:55-66.
179. Betta PG, Castagneto B, Libener R, et al. The tyrosine kinase inhibitor ZD6474 inhibits cell proliferation and induces apoptosis in malignant mesothelioma. Ann Oncol 2006;17:ix57 [abs 92PD].
180. ; NCT00597116. http://www.clinicaltrials.gov.
181. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000, 18:1185-1190.
182. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002, 110:475-482.
183. Gregorc V., Zucali P.A., Santoro A., et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor {alpha}, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010, 28:2604-2611.
184. ; NCT00309946. http://www.clinicaltrials.gov.
185. ; NCT00243074. http://www.clinicaltrials.gov.
186. ; NCT00459862. http://www.clinicaltrials.gov.
187. Mazzone M., Comoglio P.M. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006, 20:1611-1621.
188. Giaccone G., Zucali P.A. Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol 2008, 19:1219-1223.
189. Tolnay E., Kuhnen C., Wiethege T., Konig J.E., Voss B., Muller K.M. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998, 124:291-296.
190. Klominek J., Baskin B., Liu Z., Hauzenberger D. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 1998, 76:240-249.
191. Thirkettle I., Harvey P., Hasleton P.S., Ball R.Y., Warn R.M. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000, 36:522-528.
192. Jagadeeswaran R., Ma P.C., Seiwert T.Y., et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006, 66:352-361.
193. Tsao A.S., He D., Saigal B., et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007, 6:1962-1972.
194. ; NCT00509041. http://www.clinicaltrials.gov.
195. ; NCT00652574. http://www.clinicaltrials.gov.
196. Tsao AS, Wistuba II, Mehran RJ, et al. Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. Proc Am Soc Canc Org 2010 [abtr 7042].
197. Scherpereel A., Lee Y.C.G. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007, 13:339-343.
198. Robinson B.W.S., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
199. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573.
200. Creaney J., Yeoman D., Demelker Y., et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008, 3:851-857.
201. Cristaudo A., Foddis R., Vivaldi A., et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007, 17:5076-5081.
202. Lopez-Rios F., Chuai S., Flores R., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006, 66:2970-2979.
203. Borczuk A.C., Taub R.N., Hesdorffer M., et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005, 11:3303-3308.
204. Kobayashi N., Toyooka S., Yanai H., et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008, 62:120-125.
205. Kokturk N., Firat P., Akay H., et al. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005, 50:189-198.
206. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999, 189:72-78.
207. Opitz I., Soltermann A., Abaecherli M., et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardio-thoracic Surg 2008, 33:501-505.
208. Gordon G.J., Hsiao L.L., et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003, 95:598-605.
209. Gordon G.J., Rockwell G.N., Godfrey P.A., et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005, 11:4406-4414.
210. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-1521.
211. Lopez-Rios F., Chuai S., Flores R., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006, 66:2970-2979.
212. Pass H., Goparaju C., Ivanov S., et al. Hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010, 70:1916-1924.
213. Sigmond J., Backus H.H., Wouters D., et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
214. Ceppi P., Volante M., Ferrero A., et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008, 14:1059-1064.
215. Bepler G., Sommers K.E., Cantor A., et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112-1118.
216. Righi L., Capotti M.G., Ceppi P., et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010, 28:1534-1539.
217. Zucali P, Giovanetti E, Ceresoli G, et al. Thymidylate synthase and excision repair cross-complementing group 1 as predictors of responsiveness in patients with malignant pleural mesothelioma treated with pemetrexed and carboplatin. In: 10th IMIG Conference. Kyoto, Japan 2010:S21-9.
218. Zucali P., Giovannetti E., Assaraf Y.G., Ceresoli G.L., Peters G.J., Santoro A. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 2010, 21:1560-1561.